Following Vinay Prasad's abrupt departure as CBER director, FDA has asked CDER head George Tidmarsh to take on both roles while a successor is sought.

AstraZeneca's Fasenra has been cleared for use by the NHS in England as an add-on treatment for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). The final draft ...

Brain-computer interface firm Neuralink has completed a $650m financing that it says will help to "bring our technology to more people" ...

The disruption at the FDA continues with the departure of CBER director Vinay Prasad, less than three months after taking on the role.

Telehealth company Ro has a new spokesperson for its booming GLP-1 business: Serena Williams, the 23-time Grand Slam champion ...

This month’s executive moves in the agency, consultancy, and investor sectors reflect a growing emphasis on strategic ...

After UK Health Secretary Wes Streeting sent a letter to the pharma industry, warning that he will withdraw from negotiations ...

Twin Health has raised another $53 million to fund its 'digital twin' platform, which provides a model of a patient's unique ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Suzanne Aitken, SVP of managed access at Clinigen, ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

Ionis has won an FDA green light for an RNA-based hereditary angioedema (HAE) treatment, Dawnzera, that can be ...

Celcuity shares rocket on a big win for its lead drug gedatolisib in advanced breast cancer, catapulting its value to almost $1.4 billion.